Merck and Threshold Pharmaceuticals have entered into a global agreement to jointly develop and commercialise Threshold Pharmaceuticals’ hypoxia-targeted drug, TH-302, which is thought to be activated under tumour hypoxic conditions.
Under the global agreement, Merck will receive co-development rights and exclusive global commercialisation rights, and will provide Threshold with an option to co-commercialise the therapeutic in the US.
Go deeper with GlobalData
In addition, Threshold will receive an upfront payment of €19m and up to €26.5m in additional development milestones during 2012.
It is also eligible to receive a €15m milestone payment based on positive results from its randomised Phase II trial in pancreatic cancer.
According to the royalty-bearing portion of the deal, Threshold retains the option to co-promote TH-302 in the US, and Merck will be responsible for the commercialisation of TH-302 outside the US.
See Also:
TH-302 is now being investigated in a global Phase III clinical trial in patients with soft tissue sarcoma and in a randomised Phase II trial in patients with advanced pancreatic cancer, as well as additional clinical studies in other solid tumours and hematological malignancies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTo date, TH-302 has been investigated in over 550 patients in Phase I/II clinical trials in a variety of tumour types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs.
The Phase III study is a randomised multi-centre trial that is intended to investigate the use of TH-302 plus doxorubicin compared with doxorubicin alone in patients with first-line advanced soft tissue sarcoma (STS).
The randomised controlled multi-centre Phase II trial of TH-302 enrolled 214 previously untreated patients with locally advanced unrespectable or metastatic pancreatic adenocarcinoma, to investigate two different doses of TH-302 in combination with the chemotherapeutic gemcitabine when compared to gemcitabine alone.
Susan Jane Herbert, head of global business development and strategy at Merck Serono, said: "The addition of TH-302 to our pipeline provides an important opportunity in several different tumor types to expand our oncology development program."
